Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2004 1
2007 2
2008 1
2010 2
2014 3
2015 3
2016 1
2018 1
2020 1
2022 5
2023 1
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

21 results

Results by year

Filters applied: . Clear all
Page 1
Immune response and protective efficacy of the SARS-CoV-2 recombinant spike protein vaccine S-268019-b in mice.
Homma T, Nagata N, Hashimoto M, Iwata-Yoshikawa N, Seki NM, Shiwa-Sudo N, Ainai A, Dohi K, Nikaido E, Mukai A, Ukai Y, Nakagawa T, Shimo Y, Maeda H, Shirai S, Aoki M, Sonoyama T, Sato M, Fumoto M, Nagira M, Nakata F, Hashiguchi T, Suzuki T, Omoto S, Hasegawa H. Homma T, et al. Sci Rep. 2022 Dec 2;12(1):20861. doi: 10.1038/s41598-022-25418-5. Sci Rep. 2022. PMID: 36460696 Free PMC article.
Immunogenicity and protective efficacy of SARS-CoV-2 recombinant S-protein vaccine S-268019-b in cynomolgus monkeys.
Hashimoto M, Nagata N, Homma T, Maeda H, Dohi K, Seki NM, Yoshihara K, Iwata-Yoshikawa N, Shiwa-Sudo N, Sakai Y, Shirakura M, Kishida N, Arita T, Suzuki Y, Watanabe S, Asanuma H, Sonoyama T, Suzuki T, Omoto S, Hasegawa H. Hashimoto M, et al. Among authors: homma t. Vaccine. 2022 Jul 29;40(31):4231-4241. doi: 10.1016/j.vaccine.2022.05.081. Epub 2022 Jun 6. Vaccine. 2022. PMID: 35691872 Free PMC article.
Homologous and heterologous booster vaccinations of S-268019-b, a recombinant S protein-based vaccine with a squalene-based adjuvant, enhance neutralization breadth against SARS-CoV-2 Omicron subvariants in cynomolgus macaques.
Hashimoto M, Aoe S, Kawazu Y, Seki NM, Hashimoto K, Yoshihara K, Homma T, Sonoyama T, Omoto S. Hashimoto M, et al. Among authors: homma t. Vaccine. 2022 Dec 12;40(52):7520-7525. doi: 10.1016/j.vaccine.2022.10.092. Epub 2022 Nov 8. Vaccine. 2022. PMID: 36372670 Free PMC article.
Dual Targeting of Cell Wall Precursors by Teixobactin Leads to Cell Lysis.
Homma T, Nuxoll A, Gandt AB, Ebner P, Engels I, Schneider T, Götz F, Lewis K, Conlon BP. Homma T, et al. Antimicrob Agents Chemother. 2016 Oct 21;60(11):6510-6517. doi: 10.1128/AAC.01050-16. Print 2016 Nov. Antimicrob Agents Chemother. 2016. PMID: 27550357 Free PMC article.
Results from a preclinical study in rodents and a Phase 1/2, randomized, double-blind, placebo-controlled, parallel-group study of COVID-19 vaccine S-268019-a in Japanese adults.
Sonoyama T, Iwata S, Shinkai M, Iwata-Yoshikawa N, Shiwa-Sudo N, Hemmi T, Ainai A, Nagata N, Matsunaga N, Tada Y, Homma T, Omoto S, Yokokawa Shibata R, Igarashi K, Suzuki T, Hasegawa H, Ariyasu M. Sonoyama T, et al. Among authors: homma t. Vaccine. 2023 Mar 10;41(11):1834-1847. doi: 10.1016/j.vaccine.2022.12.025. Epub 2022 Dec 16. Vaccine. 2023. PMID: 36572603 Free PMC article. Clinical Trial.
Author Correction: Immune response and protective efficacy of the SARS-CoV-2 recombinant spike protein vaccine S-268019-b in mice.
Homma T, Nagata N, Hashimoto M, Iwata-Yoshikawa N, Seki NM, Shiwa-Sudo N, Ainai A, Dohi K, Nikaido E, Mukai A, Ukai Y, Nakagawa T, Shimo Y, Maeda H, Shirai S, Aoki M, Sonoyama T, Sato M, Fumoto M, Nagira M, Nakata F, Hashiguchi T, Suzuki T, Omoto S, Hasegawa H. Homma T, et al. Sci Rep. 2024 Jan 31;14(1):2599. doi: 10.1038/s41598-024-52772-3. Sci Rep. 2024. PMID: 38297027 Free PMC article. No abstract available.
21 results